Navigation Links
Fibrocell Science, Inc. Announces Addition of Dr. George J. Korkos to Board of Directors
Date:7/20/2010

EXTON, Pa., July 20 /PRNewswire-FirstCall/ -- Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that George J. Korkos, M.D., D.D.S., F.A.C.S., has been appointed to its board of directors.

Dr. Korkos currently serves as President of both Plastic Surgery Associates and Rejuva Skin Care & Laser Center (leaders in use of Botox® and fillers), each of which is located in Waukesha, Wisconsin. He also presently serves as Associate Clinical Professor at the Medical College of Wisconsin in Milwaukee.

"As a plastic surgeon and dentist with vast experience as a clinician as well as previous roles as scientific advisor to healthcare-focused companies, George will add valuable perspective to our board of directors as we begin to evaluate applications for our lead therapy in periodontics and reconstructive dentistry," said Chairman and CEO David Pernock.

Dr. Korkos was board certified in plastic surgery in 1967 and recertified in 1978. He is or has been a member of numerous prestigious medical societies, is an experienced academic lecturer and author and has presented on a variety of plastic and reconstructive surgery topics at meetings of regional and national medical associations. He has previously served as scientific advisory board member to Cellgen Company, Sleep Holding Company and Skin Visible Company. He also is Co-founder and former Contact Director and Investor of the Milwaukee Bucks Expansion Basketball Team.

Dr. Korkos pursued undergraduate studies at Marquette University, received his D.D.S. from Marquette University School of Dentistry, his M.D. and general surgery degrees from Medical College of Wisconsin, and his degree in plastic and reconstructive surgery from St. Louis University Medical School. He completed his residencies and held fellowships at Medical College of Wisconsin and St. Louis University Group of Hospitals.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence.  For additional information, please visit www.fibrocellscience.com.

Forward-Looking Statements  

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's public filings with the SEC.


'/>"/>
SOURCE Fibrocell Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The Irish Government and the Irish Voice Recognize Fibrocell Science, Inc.s Declan Daly as Irish Life Science 50 Member
2. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
3. Fibrocell Science, Inc. Enters Into Financing Agreement
4. Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
5. Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for Wrinkles
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.
8. ‘Next Big Idea' Fest Aims to Spark Interest Among NM Youth in Science, Technology as Future Career Path
9. California Life Science, Business, and Economic Development Experts Discuss Californias Bioscience Future
10. FRC: NIH Stem Cell Guidelines Reflect Poor Science, Ignore Real Hope for Patients
11. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... BERG, a biopharmaceutical company uncovering health ... announced the appointment of Jason Haddock ... Haddock brings to BERG over 20 years of ... senior financial functions at pharmaceutical companies, as well ... Niven R. Narain , BERG,s ...
(Date:2/8/2016)... Feb. 8, 2016 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... ten finalists for clean technology companies in the TSX Venture ... 10 companies listed on the TSX Venture Exchange, in each ... clean technology & life sciences, diversified industries and ... given to return on investment, market cap growth, trading volume ...
(Date:2/8/2016)... 2016  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced that it has entered into ... Technology Growth Capital, Inc. and Hercules Technology III, ... --> --> ... financing under the loan and security agreement.  The ...
(Date:2/8/2016)... -- Novan, Inc. today announced that Director Robert A. Ingram ... Novan. In addition, Robert Keegan has been appointed to ... . --> North Carolina . ... total of $32.8 million of net proceeds in a private Mezzanine ... throughout the Research Triangle area of North Carolina ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):